Lying back on his hospital bed, Brian Madeux gives a tense smile as he’s hooked up to an intravenous drip. Inside the bag of liquid above his head are billions of tiny fragments of DNA designed to be inserted into his genome, the biological instruction manual found in every cell of the body.


We are at the start of a new frontier of genomic medicine


The 44-year-old from Phoenix, Arizona, who has lived with a rare, life-threatening genetic condition known as Hunter’s Syndrome since birth, last November became the first person in the world to undergo a new type of treatment that edits genes inside his body.


Minute “molecular scissors” were added to his bloodstream to snip the DNA in his liver cells and insert a gene to repair the defective one he has carried all his life.


"We are at the start of a new frontier of genomic medicine," says Sandy Macrae, chief executive of Sangamo Therapeutics, the biotechnology firm developing the treatment. While it is still too soon to determine how successful the editing of Madeux’s genome has been, it marks a milestone in a new field of science that is widely predicted to revolutionise medicine.


As more treatments that rely on gene editing move from research laboratories into hospitals around the world, the demand for the skilled genetic engineers who make it possible is expected to soar. The UK government predicts there could be more than 18,000 new jobs created by gene and cell therapy in Britain alone by 2030, while the US Bureau of Labor Statistics estimates it will see a 7% increase in jobs for biomedical engineers and a 13% increase in medical scientists, together accounting for around 17,500 jobs.


(Credit: Getty Images)

The Francis Crick Institute is the biggest biomedical research institute under one roof in Europe with around 1250 scientists and 250 other staff (Credit: Getty Images)


But there will also be a need for people away from the laboratory bench, including those who can help make sense of the huge amounts of data that will be generated as medical treatment becomes increasingly personalised to patients’ individual genomes.


“Gene therapy is rapidly becoming an accepted and growing part of the medical research and development industry,” says Michele Calos, president of the American Society of Gene and Cell Therapy and a professor of genetics at Stanford University. “The growth of established and new gene therapy companies is expected to be accompanied by an increase in jobs, as these companies recruit scientists to staff their expanded operations.


“The gene therapy industry requires a range of graduates, with backgrounds in scientific fields like genetics, medicine, molecular biology, virology, bioengineering and chemical engineering, as well as business graduates.”


Much of the hype around gene editing lies in its ability to correct genetic defects that currently have no cure, such as cystic fibrosis and haemophilia. Many of the major pharmaceutical companies are betting on it becoming a key tool in the future of healthcare.


According to some projections, the global genome editing market is expected to double in size over the five years from 2017 to reach a value of $6.28bn (£4.84bn). Earlier this year, the UK government announced it was investing £60m ($76m) into a new cell and gene therapy manufacturing centre to help speed up the development of new treatments. In the US, the National Human Genome Research Institute predicts there will be a “considerable” increase in demand for employees in tandem with this growth.


There are already some 2,700 clinical trials using gene therapies under way or approved around the world, aiming to combat diseases as diverse as cancer, muscular dystrophy and sickle cell anaemia. Most of the small gene therapy companies behind these trials have partnerships or have received investment from much bigger drug firms, including BayerGlaxoSmithKline, Pfizer, Merck and Novartis. A quick search on recruitment websites reveals most of these pharma firms are actively seeking to hire their own gene therapy scientists too.


The gene therapy industry requires a range of graduates, with backgrounds in scientific fields like genetics, medicine, molecular biology, virology, bioengineering and chemical engineering, as well as business graduates


One reason for the rise in demand for skilled workers is the huge range of expertise likely to be needed as gene therapies begin to become available.


“It is a really multi-disciplinary field,” says Güneş Taylor, a researcher at The Francis Crick Institute in London. She has been using gene editing techniques as part of her studies on the sex chromosomes, which could eventually be used to help people with fertility problems or developmental sex disorders such as Rokitansky syndrome, where girls can be born without a womb. “We need molecular scientists, engineers and computer scientists to help us interpret the huge amounts of data modern genetic techniques produce,” she says.


(Credit: Getty Images)

Projects that involve altering existing genetic material remain controversial (Credit: Getty Images)


While salaries will depend on the qualifications needed for each role, they are likely to be higher than average due to the high skill levels required. Medical geneticists, for example, can expect to earn between $39,870 and $134,770 annually while a bioinformatician, who helps to interpret genetic data, would earn $35,620-$101,030 a year, according to the National Human Genome Research Institute.


“There is a lot of hype around gene editing and if even some of those are to be realised, it will involve a lot of people doing research,” says Taylor. “But as treatments start to emerge, we will also need clinicians and ethicists to help us with some of the issues that might be involved.”


Taylor uses a powerful new gene editing tool known as CRISPR-Cas9, which harnesses part of the defence mechanism used by bacteria to edit genes in other organisms. Its invention five years ago has transformed the speed and cost of editing genes, allowing scientists to accurately delete troublesome genes or create precise breaks in the DNA where new genes can be inserted. It has spurred a surge in research to identify defective genes in diseases.


While not many diseases can simply be turned off by deleting these defective genes, CRISPR-Cas9 has opened a new door for treating patients and unravelling how other conditions might be tackled.


“It is such an exciting time to be a molecular biologist,” says Taylor. “I have wanted to be a scientist since I was 15 years old and ended up working on gene editing by chance. There can be days where I’m in the laboratory doing repetitive work, but every day is different and it lets me pursue answers to some big questions.”


(Credit: Getty Images)

Gene editing tool CRISPR-Cas9, invented by Jennifer Doudna, has revolutionised the speed and cost of editing genes (Credit: Getty Images)


However, the scale at which the potential of gene editing can be realised will depend on how the regulatory environment evolves over the coming years. It remains a controversial approach because little is known about the long-term effects of altering a person’s DNA. Unintended changes could cause cells to turn cancerous, for example, or could trigger an immune response if the patient’s body reacts to the introduced gene.


There are ethical issues too, particularly surrounding the editing of genes in egg and sperm cells rather than those of other adult cells in the body. This could be used to combat diseases that are passed down through families, generation to generation, but it also raises the prospect of tinkering with other traits like eye colour or height.


For this reason, genetic editing of plants, animals and humans is extremely tightly controlled in places like Europe, while in the US, slightly more relaxed rules have allowed some clinical trials to go ahead.


China is currently leading the world in gene editing. Earlier this year it emerged that it had approved clinical trials involving 300 patients that will use CRISPR-Cas9 to treat a range of conditions. Scientists in China have also already used the technique to treat 86 patients suffering from cancer and HIV.


While many of China’s gene therapy pioneers were trained abroad, they are now teaching a new generation of medical students how to use techniques like CRISPR within the country. The Chinese government has also prioritised gene editing as part of its latest five-year plan that will see billions of dollars ploughed into research.


But as gene editing begins to be used on patients, there are some who are uncomfortable with the idea of tinkering with the code that gives each of us life. Already the use of genetics to diagnose diseases that can be passed to children and grandchildren is leading to a rapid increase in another occupation that just a few years ago did not exist - genetic counsellors.


“As patients and medical staff have to take difficult decisions that involve genetics, they will need support to interpret the information they are being given,” says Christine Patch, vice president of the European Society for Human Genetics and a genetic counsellor.


 Medical geneticists, for example, can expect to earn between $39,870 and $134,770 annually while a bioinformatician, who helps to interpret genetic data, would earn $35,620-$101,030 a year, according to the National Human Genome Research Institute


The US Bureau of Labor Statistics ranks genetic counsellors as one of its top 20 fastest growing jobs. It predicts the number of jobs available for experts who can interpret genetic information, offer support and advice to medical staff and guide patients through the decisions they will need to take will increase by 29% by 2026.


“Gene therapy is going to involve some difficult choices for patients and they will need to consider the risks just as they would with any other treatment,” warns Patch. “To do this they will need to be able to understand what is involved. Healthcare professionals will also need to increase their genetics knowledge and there is going to be a growing role for people with an expertise in this.”


By Richard Gray